Creo Medical Group PLC
LSE:CREO
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.125
48.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Creo Medical Group PLC
Creo Medical Group PLC
Cost of Revenue
Creo Medical Group PLC
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Creo Medical Group PLC
LSE:CREO
|
Cost of Revenue
-£15.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-449%
|
CAGR 10-Years
N/A
|
|
|
Smith & Nephew PLC
LSE:SN
|
Cost of Revenue
-$1.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Cost of Revenue
-$400.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-31%
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Cost of Revenue
-£26.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
|
Angle PLC
LSE:AGL
|
Cost of Revenue
-£626k
|
CAGR 3-Years
-51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Belluscura PLC
LSE:BELL
|
Cost of Revenue
-$1.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
Creo Medical Group PLC
Glance View
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.
See Also
What is Creo Medical Group PLC's Cost of Revenue?
Cost of Revenue
-15.3m
GBP
Based on the financial report for Jun 30, 2024, Creo Medical Group PLC's Cost of Revenue amounts to -15.3m GBP.
What is Creo Medical Group PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-449%
Over the last year, the Cost of Revenue growth was -1%. The average annual Cost of Revenue growth rates for Creo Medical Group PLC have been -8% over the past three years , -449% over the past five years .
You don't have any saved screeners yet
